Therapeutic value of mepitiostane in the treatment of advanced breast cancer

A new, orally active antiestrogenic steroid, mepitiostane (20 mg/day), was given to 45 patients with advanced breast cancer. The regression rate was 31.1%, or 14 of 45 patients, and a duration of regression of greater than 6 months was obtained in seven patients. Virilizing effects such as hoarsenes...

Full description

Bibliographic Details
Published in:Motor evoked potentials induced by electrical stimulation of the spine in dogs : which structures are involved?, Vol. 62, No. 5 (1978), p. 743-5
Main Author: Inoue, K (Author)
Other Involved Persons: Okazaki, K ; Morimoto, T ; Hayashi, M ; Uyama, S ; Sonoo, H ; Koshiba, Y ; Takihara, T ; Nomura, Y ; Yamagata, J ; Kondo, H ; Kanda, K ; Takenaka, K
Format: Article
Language:English
Item Description:Date Completed 01.09.1978
Date Revised 17.11.2004
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Subjects:
Journal Article
Androstanes > adverse effects > *therapeutic use
Breast Neoplasms > *drug therapy
Estrogen Antagonists > adverse effects > *therapeutic use
Female
Humans
Sulfides > adverse effects > therapeutic use
Androstanes
Estrogen Antagonists
Sulfides
QR Code: Show QR Code
Cover Image
Not owned by UB Ilmenau
Published in:
Motor evoked potentials induced by electrical stimulation of the spine in dogs : which structures are involved?, Vol. 62, No. 5 (1978), p. 743-5
Feedback Delivery Service